Aptar Pharma Introduces Collaborative System-Level Framework to Advance Injectable Drug Delivery Development
Aptar Pharma, a global leader in drug delivery, dosing, protection technologies, and pharmaceutical services, has announced the launch of a new collaborative system-level framework designed to support the development of injectable drug delivery systems. The initiative represents a significant step toward helping pharmaceutical and biotechnology companies gain earlier insights into the performance of complete injectable systems, enabling more informed development decisions while supporting the delivery of safe, effective, and high-quality therapies to patients.
Building on more than a decade of experience supporting pharmaceutical customers in respiratory and ophthalmic drug development, Aptar Pharma is extending its expertise to injectable therapies through a collaborative model that brings together component manufacturers, technology partners, and integrated testing capabilities. The framework is intended to generate comprehensive data packages that evaluate assembled injectable systems rather than individual components alone, providing developers with a broader understanding of system performance during the early stages of product development.
The company believes this integrated approach will become increasingly valuable as the pharmaceutical industry continues to develop more complex biologics, highly sensitive vaccines, and combination drug-device products that require sophisticated packaging and delivery solutions.
Responding to the Growing Complexity of Injectable Medicines
Injectable therapies have become one of the fastest-growing segments of the pharmaceutical industry. Advances in biotechnology have led to an increasing number of biologic medicines, monoclonal antibodies, gene therapies, and advanced vaccines entering clinical development and commercial use.
Many of these products are highly sensitive to environmental conditions and require carefully engineered container closure systems to maintain stability, sterility, and effectiveness throughout their lifecycle.
At the same time, pharmaceutical companies face increasing regulatory expectations related to the performance of complete drug delivery systems rather than evaluating packaging components individually.
Recognizing these challenges, Aptar Pharma has developed a collaborative framework that supports earlier evaluation of complete injectable systems while providing manufacturers with critical performance data that can guide product development and reduce technical risk.
Building on Decades of Injectable Expertise
Aptar Pharma’s Injectables division brings more than 60 years of experience in designing and manufacturing elastomeric components used in injectable drug delivery systems.
Over the decades, the company has developed a broad portfolio of products that support pharmaceutical manufacturers around the world, including elastomeric closures, plungers, needle shields, and other critical components designed to preserve drug integrity and ensure reliable delivery.
The new collaborative framework builds upon this longstanding expertise by integrating Aptar Pharma’s component technologies with those of leading partners across the injectable drug delivery value chain.
Instead of evaluating components independently, the company now aims to assess the assembled system as a whole, generating valuable information about how individual components interact under real-world conditions.
Supporting Earlier Development Decisions
One of the primary goals of the new framework is to provide pharmaceutical companies with earlier visibility into the performance of assembled injectable systems.
Traditionally, container closure systems have often been assessed one component at a time. This fragmented approach typically requires coordination among multiple suppliers, with system integration challenges often emerging later in development.
As products advance toward commercialization, unexpected compatibility issues between components can increase development timelines, introduce technical risks, and require costly redesign efforts.
Aptar Pharma’s collaborative strategy seeks to reduce these challenges by enabling earlier system-level evaluations.
By generating integrated performance data before late-stage development, pharmaceutical companies can better understand how complete delivery systems perform, allowing them to make more informed decisions regarding packaging selection, manufacturing strategies, and clinical development.
Collaboration Across the Injectable Value Chain
A key feature of Aptar Pharma’s initiative is its emphasis on strategic partnerships.
Rather than working independently, the company is collaborating with organizations across the injectable drug delivery ecosystem, including manufacturers of pre-filled syringe (PFS) platforms and other packaging technologies.
These collaborations allow multiple components to be evaluated together within complete delivery systems.
The current framework focuses on partner pre-filled syringe platforms that incorporate:
- Aptar Pharma rigid needle shields (RNS)
- PremiumCoat® elastomeric plungers
- Technologies designed for sensitive formulations
- Components suitable for highly viscous biologic medicines
Through these integrated evaluations, developers gain a more comprehensive understanding of assembled-system performance than would typically be possible through isolated component testing.
Addressing the Needs of Modern Biologics
Biologic medicines present unique formulation and delivery challenges compared with traditional small-molecule drugs.
Many biologics possess:
- High viscosity
- Temperature sensitivity
- Complex molecular structures
- Increased susceptibility to contamination
- Strict stability requirements
These characteristics place significant demands on packaging materials and container closure systems.
Even subtle interactions between drug formulations and elastomeric components may affect product quality, making comprehensive system evaluation increasingly important.
Aptar Pharma’s collaborative framework is designed specifically to address these challenges by generating data that examine interactions among critical packaging components before products enter large-scale manufacturing.
Aligning with USP <382> Expectations
An important driver behind Aptar Pharma’s new initiative is the evolving regulatory landscape.
The company noted that pharmaceutical developers are increasingly seeking approaches that support the expectations outlined in United States Pharmacopeia (USP) Chapter <382>, which places greater emphasis on understanding assembled container closure systems rather than evaluating components independently.
The new framework has been designed to support these principles by generating integrated performance information across complete injectable systems.
Although pharmaceutical manufacturers remain responsible for demonstrating the suitability and regulatory compliance of their final packaging systems, Aptar Pharma believes that earlier access to system-level data can simplify development while strengthening overall confidence in packaging performance.
Comprehensive Data Packages
As part of the initiative, Aptar Pharma is developing comprehensive data packages covering multiple aspects of injectable system performance.
These evaluations include:
- Functional performance testing
- Container closure integrity testing (CCIT)
- Sealing performance assessments
- Evaluation of component interactions
- System compatibility analysis
- Performance under representative conditions
Rather than relying on isolated test results from individual suppliers, customers receive integrated information describing how the complete assembled system performs.
This broader perspective enables development teams to identify potential issues earlier while improving coordination among manufacturing partners.
Supporting Better Risk Management
Drug development programs often involve significant financial investments and complex regulatory pathways.
Unexpected packaging or delivery system issues identified during late-stage development can delay regulatory submissions, increase manufacturing costs, or require additional validation studies.
By introducing system-level testing earlier in development, Aptar Pharma aims to help customers manage these risks more effectively.
The framework supports pharmaceutical companies by helping them:
- Make earlier container closure decisions
- Develop testing strategies aligned with regulatory expectations
- Build confidence before commercial scale-up
- Reduce uncertainty during product development
- Improve communication among supply chain partners
Early access to assembled-system performance information may also reduce the likelihood of unexpected technical challenges as products move toward commercialization.
Flexible Solutions for Diverse Therapeutic Needs
Not all injectable medicines require identical packaging configurations.
Different biologics, vaccines, and injectable formulations possess unique characteristics that influence packaging selection.
Factors affecting system design include:
- Drug molecule properties
- Manufacturing processes
- Delivery requirements
- Storage conditions
- Regulatory strategies
- Commercial distribution needs
Recognizing this diversity, Aptar Pharma designed its collaborative framework to remain flexible rather than offering a single standardized solution.
The company intends to support multiple development pathways through a combination of:
- Various supply options
- High-quality elastomeric components
- Collaborative partnerships
- Relevant performance datasets
- System-specific testing approaches
This flexibility allows pharmaceutical companies to select packaging configurations best suited to their individual products.
Executive Perspective
Commenting on the announcement, Audrey Chardonnet, Vice President of Global Market Development for Aptar Pharma Injectables, highlighted the increasing complexity of injectable medicines and the growing importance of system-level understanding.
She explained that the rapid expansion of biologics and combination products has increased industry focus on evaluating complete injectable systems in accordance with evolving USP <382> principles.
According to Chardonnet, Aptar Pharma’s collaborative approach is intended to help customers make more informed development decisions while preserving the flexibility needed to support a wide range of molecules, drug formulations, and delivery formats.
She emphasized that system-level insights can provide valuable information throughout development without limiting customers’ ability to tailor packaging solutions to their specific therapeutic requirements.
Continuing Expansion of the Framework
The current initiative represents only the first stage of Aptar Pharma’s broader strategy.
The company announced plans to gradually introduce additional collaborations with partners across the injectable drug delivery industry.
Each new collaboration will focus on generating system-specific performance data addressing different packaging configurations, therapeutic applications, and development needs.
Future data packages are expected to support an expanding range of biologics, vaccines, and advanced injectable medicines as the pharmaceutical industry continues to evolve.
Aptar Pharma’s new collaborative system-level framework reflects the growing importance of integrated approaches to injectable drug development. As biologics, vaccines, and combination products become increasingly sophisticated, pharmaceutical companies require earlier and more comprehensive insights into how complete delivery systems perform under real-world conditions.
By combining decades of expertise in elastomeric components with strategic partnerships across the injectable value chain, Aptar Pharma aims to simplify development, improve risk management, and support regulatory expectations through comprehensive system-level data packages. While pharmaceutical manufacturers remain responsible for validating their final drug product packaging and delivery systems, the company’s collaborative framework offers a valuable resource for making informed decisions earlier in development.
As additional partnerships and data packages are introduced, Aptar Pharma expects the initiative to play an increasingly important role in advancing innovative injectable therapies and improving patient access to safe, reliable, and effective medicines worldwide.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries.